Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPYVLP04
- Development stage
- Preclinical
- Lead developer
- SpyBiotech
- Modality
- Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Injection
01
Overview
SPYVLP04 is a preclinical virus-like particle (VLP) vaccine candidate being developed by SpyBiotech for the prevention of Epstein-Barr virus (EBV) infection. The vaccine is built using SpyBiotech's proprietary protein "superglue" technology (SpyTag/SpyCatcher), which allows for the stable and high-density display of EBV antigens on a VLP platform. This presentation is intended to trigger a potent immune response, potentially addressing the unmet need for a vaccine against EBV, a virus linked to infectious mononucleosis, multiple sclerosis, and several types of cancer.
- Other names
- SPYVLP
02
Targets
gL (Epstein-Barr virus glycoprotein L)
Beyond the preview
Go deeper on SPYVLP04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPYVLP04.